

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
51752-US-PCT
APPLICATION NO.
10/593,135
APPLICANT
ABLA CREASEY
FILING DATE
SEPTEMBER 18, 2006

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA	RE 36,476	12/28/99	Khoury et al.			
	AB	4,599,176	7/8/86	Wittenberger			
	AC	5,276,015	1/4/94	Khoury et al.			
	AD	5,736,364	4/7/98	Kelley et al.			
	AE	5,859,005	1/12/99	Mohan et al.			
	AF	5,874,407	2/23/99	Kelley et al.			
	AG	5,885,781	3/23/99	Johnson et al.			
	AH	5,888,968	3/30/99	Chen et al.			
	AI	5,902,582	5/11/99	Hung			
	AJ	5,914,316	6/22/99	Brown et al.			
	AK	5,977,057	11/2/99	Van't Veer et al.			
	AL	5,981,471	11/9/99	Papathanassin et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO	
	AM	WO 93/24143	12/9/93	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AN	WO 93/25230	12/23/93	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AO	WO 99/00418	1/7/99	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AP	WO 01/49315	7/12/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	AQ	WO 01/60837	8/23/01	PCT			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	BAJAJ et al. "Tissue factor pathway inhibitor Expression by Human Pleural Mesothelial and Mesothelioma Cells", <i>Eur. Respir. J.</i> , Vol. 15, pp. 1069-1078 (2000).
	AS	DEHOUX et al., "Compartmentalized Cytokine Production within the Human Lung in Unilateral Pneumonia", <i>Am. J. Respir. Crit. Care Med.</i> , Vol. 150, pp. 710-716 (1994).
	AT	BOUTTEN et al., "Compartmentalized IL-8 and Elastase Release within the Human Lung in Unilateral Pneumonia", <i>Am. J. Respir. Crit. Care Med.</i> , Vol. 153, pp. 336-342 (1996).

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
51752-US-PCT
APPLICATION NO.
10/593,135
APPLICANT
ABLA CREASEY
FILING DATE
SEPTEMBER 18, 2006

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA	5,212,091	5/18/93	Diaz-Collier et al.			
	BB	5,563,123	10/8/96	Innis et al.			
	BC	6,008,199	12/28/99	Grinnell et al.			
	BD	6,060,449	5/9/00	Hamuro et al.			
	BE	6,156,734	12/5/00	Grinnell et al.			
	BF	6,159,468	12/12/00	Carlson et al.			
	BG	6,180,607	1/30/01	Davies et al.			
	BH	6,238,878	5/29/01	Jakobsen et al.			
	BI	6,242,414	6/5/01	Johnson et al.			
	BJ	6,268,344	7/31/01	Grinnell et al.			
	BK	6,270,764	8/7/01	Fisher et al.			
	BL	6,294,648	9/25/01	Delaria et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BM	WO 03/032904	4/24/03	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BN	EP 268110 B1	5/25/88	Europe			<input type="checkbox"/>	<input type="checkbox"/>
	BO	EP 270799 B1	6/15/88	Europe			<input type="checkbox"/>	<input type="checkbox"/>
	BP	EP 318451 B1	5/31/89	Europe			<input type="checkbox"/>	<input type="checkbox"/>
	BQ	EP 473564 A1	3/4/92	Europe			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	DE MOERLOOSE et al., "Procoagulant activity in bronchoalveolar fluids" No relationship with tissue factor pathway inhibitor activity", <i>Thrombosis Research</i> , Vol. 65, pp. 507-518 (1992).
	BS	FELDMAN et al., "Anti-TNF alpha therapy is useful in rheumatoid arthritis and Crohn's disease: Analysis of the mechanism of action predicts utility in other diseases", <i>Transplantation Proc.</i> , Vol. 30, No. 8, pp. 4126-4127 (December 1998).
	BT	GÜNTHER et al. "Alveolar Fibrin Formation Caused by Enhanced Procoagulant and Depressed Fibrinolytic Capacities in Severe Pneumonia", <i>Am. J. Respir. Crit. Care Med.</i> , Vol. 161, pp 454-462 (2000).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
51752-US-PCT
APPLICATION NO.
10/593,135
APPLICANT
ABLA CREASEY
FILING DATE
SEPTEMBER 18, 2006

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA	6,323,326	11/27/01	Dorin et al.			
	BB	6,344,197	2/5/02	Fisher et al.			
	BC	6,395,270	5/28/02	Carlson et al.			
	BD	6,444,434	9/3/02	Jakobsen et al.			
	BE	6,489,296	12/3/02	Grinnell et al.			
	BF	6,525,102	2/25/03	Chen et al.			
	BG	2001/0006806	7/5/01	Fisher et al.			
	BH	2001/0018204	8/30/01	Papathanassin et al.			
	BI	2001/0028880	10/11/01	Fisher et al.			
	BJ	2001/0051154	12/13/01	Roemisch et al.			
	BK	2002/0006896	1/17/02	Johnson et al.			
	BL	2002/0006897	1/17/02	Johnson et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BM	EP 473564 B1	3/4/92	Europe			<input type="checkbox"/>	<input type="checkbox"/>
	BN	WO 85/04899	11/7/85	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BO	WO 90/08158	7/26/90	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BP	WO 91/02753	3/7/91	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BQ	WO 91/19514	12/26/91	PCT			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	SCHAAF et al., "Neutrophil Inflammation and Activation in Bronchiectasis: Comparison with Pneumonia and Idiopathic Pulmonary Fibrosis", <i>Respiration</i> , Vol. 67, pp. 52-59 (2000).
	BS	VAN'T VEER et al., "Inhibitory Mechanism of the Protein C Pathway on Tissue Factor-induced Thrombin Generation", <i>The J. of Biological Chemistry</i> , Vol. 272, No. 12, pp. 2982-7994 (March 21, 1997).
	BT	ABRAHAM, "Tissue Factor Inhibition and Clinical Trial Results of Tissue Factor Pathway Inhibitor in Sepsis", <i>Critical Care Medicine</i> , Vol. 28, No. 9, pp. S31-S33 (2000).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
51752-US-PCT
APPLICATION NO.
10/593,135
APPLICANT
ABLA CREASEY
FILING DATE
SEPTEMBER 18, 2006

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA	2002/0032150	3/14/02	Johnson et al.			
	BB	2002/0137884	9/26/02	Dorin et al.			
	BC	2002/0177560	11/28/02	Greenfield et al.			
	BD	2002/0177563	11/28/02	Griffin et al.			
	BE	2002/0197667	12/26/02	Inis et al.			
	BF	2002/0198138	12/26/02	Macias			
	BG	2003/0007966	1/9/03	Hoffman et al.			
	BH	2003/0022354	1/30/03	Gerfitz et al.			
	BI	2003/0073638	4/17/03	Kjalke			
	BJ	4,179,337	12/18/79	Davis et al.			
	BK	4,399,216	8/16/83	Axel et al.			
	BL	4,495,285	1/22/85	Shimizu et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BM	WO 92/06711	4/30/92	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BN	WO 92/07584	5/14/92	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BO	WO 93/25230	12/23/93	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BP	WO 00/77254	12-2000	PCT			<input type="checkbox"/>	<input type="checkbox"/>
	BQ	WO 96/40784	12/19/96	PCT			<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	ABRAHAM, "Coagulation Abnormalities in Acute Lung Injury and Sepsis", <i>Am. J. Respir. Cell Mol. Biol.</i> , Vol. 22, No. 4, pp. 401-404 (April 2000).
	BS	ABRAHAM et al., "Efficacy and Safety of Titacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis; A Randomized Controlled Trial", <i>JAMA</i> , Vol. 290, No. 2, pp. 238-247, American Medical Association (July 9, 2003).
	BT	ALBAN et al., "Plasma Levels of Total and Free Tissue Factor Pathway Inhibitor (TFP1) as Individual Pharmacological Parameters of Various Heparins", <i>Thromb. Haemost.</i> , Vol. 85, No. 5, pp. 824-829 (May 2001).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
51752-US-PCT
APPLICATION NO.
10/593,135
APPLICANT
ABLA CREASEY
FILING DATE
SEPTEMBER 18, 2006

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA	4,511,502	4/16/85	Builder et al.			
	BB	4,530,787	7/23/85	Shaked et al.			
	BC	4,569,790	2/11/88	Koths et al.			
	BD	4,572,798	2/25/86	Koths et al.			
	BE	4,603,106	7/29/86	Carami et al.			
	BF	4,609,546	9/2/88	Hiratani			
	BG	4,620,948	11/4/88	Builder et al.			
	BH	4,683,195	7/28/87	Mullis et al.			
	BI	4,683,202	7/28/87	Mullis et al.			
	BJ	4,711,845	12/8/87	Gelfand et al.			
	BK	4,748,234	5/31/88	Dorin et al.			
	BL	4,766,106	8/23/88	Katre et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BM						<input type="checkbox"/>	<input type="checkbox"/>
	BN						<input type="checkbox"/>	<input type="checkbox"/>
	BO						<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	AMERI et al., "Expression of Tissue Factor Pathway Inhibitor by Cultured Endothelial Cells in Response to Inflammatory Mediators", <i>Blood</i> , Vol. 79, pp. 3219-3226 (1992).
	BS	ANGUS et al., "Unraveling Severe Sepsis: Why did OPTIMIST Fail and What's Next?", <i>JAMA</i> , Vol. 290, No. 2, pp. 256-258, "American Medical Association (July 9, 2003).
	BT	BADIMON, "Potential Therapeutic Indications for Tissue Factor Inhibition", The IBC International Symposium on Advances in Anti-coagulant, Anti-thrombotic and Thrombolytic Drugs (September 11, 1998).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
51752-US-PCT
APPLICATION NO.
10/593,135
APPLICANT
ABLA CREASEY
FILING DATE
SEPTEMBER 18, 2006

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	BA	4,847,201	7/11/89	Kawasaki et al.			
	BB	4,929,700	5/29/90	Halenbeck et al.			
	BC	4,968,852	10/30/90	Wun et al.			
	BD	5,106,833	4/21/92	Broze et al.			
	BE	5,110,730	5/5/92	Edgington et al.			
	BF	5,219,994	6/15/93	Buonassisi et al.			
	BG	5,223,427	6/29/93	Edgington et al.			
	BH	6,063,764	5/16/00	Creasey et al.			
	BI	6,824,997	11/2004	Moore et al.			
	BJ	6,660,852	12/2003	Keshi et al.			
	BK	6,011,136	1/4/00	Dreyfuss et al.			
	BL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	BM						<input type="checkbox"/>	<input type="checkbox"/>
	BN						<input type="checkbox"/>	<input type="checkbox"/>
	BO						<input type="checkbox"/>	<input type="checkbox"/>
	BP						<input type="checkbox"/>	<input type="checkbox"/>
	BQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	BR	BAILEY et al. "Methylmercury as a Reversible Denaturing Agent for Agarose Gel Electrophoresis", <i>Anal. Bioch.</i> , Vol. 70, pp. 75-85 (1976).
	BS	BAJAJ et al., "Cultured Normal Human Hepatocytes do not Synthesize Lipoprotein-Associated Coagulation Inhibitor: Evidence that Endothelium is the Principal Site of Its Synthesis", <i>PNAS (USA)</i> , Vol. 87, pp. 8869-8873 (1990).
	BT	BAJAJ et al., Inhibitor of the Factor Vita-Tissue Factor complex is Reduced in Patients with Disseminated Intravascular Coagulation but not in Patients with Severe Hepatocellular Disease", <i>J. Clin. Invest.</i> , Vol. 79, pp. 1874-1878 (1987).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
51752-US-PCT
APPLICATION NO.
10/593,135
APPLICANT
ABLA CREASEY
FILING DATE
SEPTEMBER 18, 2006

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	BEVILACQUA et al., "Recombinant Tumor Necrosis Factor Induces Procoagulant Activity in Cultured Human Vascular Endothelial Cells: Characterization and Comparison with the Actions of Interleukin 1", <i>PNAS (USA)</i> , Vol. 83, pp. 4533-4537 (1986).
	DB	BOLIVAR et al., "Construction and Characterization of New Cloning Vectors", <i>Gene</i> , Vol. 2, pp. 95-113 (1977).
	DC	BONE et al., "Definitions for Sepsis and Organ Failure and guidelines for the Use of Innovative Therapies in Sepsis", <i>Chest</i> , Vol. 101, pp. 1644-1655 (1992).
	DD	BOOSMAN et al., "Nontraditional Method Used to Determine The Disulfide Bonds of Human Tissue Factor Pathway Inhibitor from E. Coli", 11 th International conference on Methods in Protein Structure Analysis (September 5, 1998).
	DE	BRAECKMAN et al., "Population PK/PD Modeling and Computer assisted Trial Design (CATD) in Clinical Drug Development - A Case Example, 8 th Annual Workshop on Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis at Marina del Ray, CA (June 25-26, 1999).
	DF	BROACH, "Construction of High Copy Yeast Vectors Using 2-µm Circle Sequences", <i>Methods in Enzymology</i> , Vol. 101, pp. 307-325 (1983).
	DG	BROACH et al., "Transformation in Yeast Development of a Hybrid Cloning Vector and Isolation of the CAN1 Gene", <i>Gene</i> , Vol. 8, pp. 121-133 (1979).
	DH	BROZE et al., "Regulation of Coagulation by a Multivalent Kunitz-Type Inhibitor", <i>Biochemistry</i> , Vol. 29, pp. 7539-7546 (1990).
	DI	BROZE et al., "The Lipoprotein-Associated Coagulation Inhibitor that inhibits the Factor VII-Tissue Factor Complex Also Inhibits Factor Xa: Insight Into its Possible Mechanism of Action", <i>Blood</i> , Vol. 71, pp. 335-343 (1988).
	DJ	BROZE et al., "Isolation of the Tissue Factor Inhibitor Produced by HepG2 Hepatoma Cells", <i>PNAS (USA)</i> , Vol. 84, pp. 1886-1890 (1987).
	DK	BROZNA, "Cellular Regulation of Tissue Factor", <i>Blood Coagulation Fibrinolysis</i> , Vol. 1, pp. 415-426 (1990).
	DL	CALLANDER et al., "Mechanisms of Binding of Recombinant Extrinsic Pathway Inhibitor (rEPI) to Cultured Cell Surfaces", <i>The Journal of Biological Chemistry</i> , Vol. 267, pp. 876-882 (1992).
	DM	CAMEROTA et al., "Delayed Treatment with Recombinant Human Tissue Factor Pathway Inhibitor Improves Survival in Rabbits with Gram-Negative Peritonitis", <i>J. Infect. Dis.</i> , Vol. 177, No. 3, pp. 668-76 (March 1998).
	DN	CLARKE et al., "Electron Procedure for Isolation of Centromere DNAs from <i>Saccharomyces Cerevisiae</i> ", <i>Meth. Enzymol.</i> , Vol. 101, pp. 300-325 (1983).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
51752-US-PCT
APPLICATION NO.
10/593,135
APPLICANT
ABLA CREASEY
FILING DATE
SEPTEMBER 18, 2006

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA	CLEWELL et al. "Nature of Col E ₁ , Plasmid Replication in Escherichia coli in the Presence of Chloramphenicol", <i>J. Bacteriol.</i> , Vol. 110, pp. 667-676 (1972)
DB	CLEWELL et al., "Supercoiled Circular DNA-Protein Complex in Escherichia Coli: Purification and Induced Conversion to an Open Circular DNA Form", <i>PNAS (USA)</i> , Vol. 62, pp. 1159-1166 (1969)
DC	COHEN et al., "Nonchromosomal Antibiotic Resistance in Bacteria: Genetic Transformation of Escherichia Coli by R-Factor DNA", <i>PNAS (USA)</i> , Vol. 69, pp. 2110-2114 (1972).
DD	COLUCCI et al., "Cultured Human Endothelial Cells Generate Tissue Factor in Response to Endotoxin", <i>J. Clin. Invest.</i> , Vol. 71, pp. 1893-1896 (1983).
DE	CORRIGAN, "Heparin Therapy in Bacterial Septicemia", <i>J. Pediatrics.</i> , Vol. 91, pp. 695-700 (1977).
DF	CORRIGAN et al., "Heparin Therapy in Septicemia with Disseminated Intravascular Coagulation. Effect on Mortality and on Correction of Hemostatic Defects", <i>N. Engl. J. Med.</i> , Vol. 283, pp. 778-782 (1970).
DG	CREASEY, "New Potential Therapeutic Modalities: Tissue Factor Pathway Inhibitor", <i>Sepsis.</i> , Vol. 3, pp. 173-182 (1999).
DH	CREASEY et al., "Tissue Factor Pathway Inhibitor Activity in Severe Sepsis", <i>Crit. Care Med.</i> , Vol. 29(7 Suppl.): pp. S126-S129 (2001).
DI	CREASEY, "TFPI Biology and Pharmacology", IBC 9 th Annual Conference on Sepsis, Endotoxemia & Related Disorders (January 20, 1999).
DJ	CREASEY, "Investigation of Tifacogin (Recombinant Tissue Factor Pathway Inhibitor) in Severe Sepsis", ICAAC Meeting (September 26, 1999).
DK	CREASEY, "Investigation of Tifacogin (rTFPI) for Severe Sepsis", <i>Crit. Care Med.</i> (October 28, 1999).
DL	CREASEY, "Investigation of Tifacogin (rTFPI) for Severe Sepsis", 5 th World Congress on Trauma, Shock, Inflammation and Sepsis (November 30, 1999)
DM	CREASEY et al., "Tissue Factor Pathway Inhibitor Reduces Mortality from Escherichia Coli Septic Shock", <i>J. Clin. Invest.</i> , Vol. 91 pp. 2850-2869 (June 1993).
DN	CREASEY et al., "Endotoxin and Cytokine Profile in Plasma of Baboons Challenged with Lethal and Sublethal Escherichia coli", <i>Circ. Shock</i> , Vol. 33, pp. 84-91 (1991).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
51752-US-PCT
APPLICATION NO.
10/593,135
APPLICANT
ABLA CREASEY
FILING DATE
SEPTEMBER 18, 2006

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA	CROSS et al., "Choice of Bacteria in Animal Models of Sepsis", <i>Infect. Immun.</i> , Vol. 61, pp. 2741-2747 (1993).
DB	DAY et al., "Recombinant Lipoprotein-Associated Coagulation Inhibitor Inhibits Tissue Thromboplastin-Induced Intravascular Coagulation in the Rabbit". <i>Blood</i> , 76, No. 8, pp. 1538-1545 (October 15, 1990).
DC	DEJONGE et al., "Tissue Factor Pathway Inhibitor Dose-Dependently Inhibits Coagulation Activation without Influencing the Fibrinolytic and Cytokine Response During Human Endotoxemia", <i>Blood</i> , Vol. 95, No. 4, pp. 1124-1129 (February 15, 2000).
DD	DEJONGE et al., "Tissue Factor Pathway Inhibitor Does Not Influence Inflammatory Pathway During Human Endotoxemia", <i>J. Infect. Dis.</i> , Vol. 183, No. 12, pp. 1815-1818 (June 2001).
DE	DEPICKER et al., "Nopaline Synthase: Transcript Mapping and DNA Sequence", <i>J. Mol. Appl. Gen.</i> , Vol. 1- pp. 561-573 (1982).
DF	DHAINAUT et al., "Combined Procoagulant and Innate Immune Response to Infection: Toward More Potent Drugs in Septic Patients", <i>Crit. Care Med.</i> , Vol. 29, No. 1, pp. 205-207 (January 2001).
DG	FIERS et al., "Complete Nucleotide sequence of SV40 DNA", <i>Nature</i> , Vol. 273, pp. 113-120 (1978).
DH	FINK et al., "Laboratory Models of Sepsis and Septic Shock", <i>Journal of Surgical Research</i> , Vol. 49, pp. 186-196 (1990)
DI	FISCHER et al., "Interleukin-Receptor Blockade Improves Survival Hemodynamic Performance in <i>Escherichia Coli</i> Septic Shock, but Fails to Alter Host Responses to Sublethal Endotoxemia", <i>J. Clin. Invest.</i> , Vol. 89, pp. 1551-1557 (1992).
DJ	GIRARD et al., "Truncated Tissue Factor Pathway Inhibitor Protects Baboons from Lethal Doses of <i>E. Coli</i> ", <i>Blood, Coagulation & Fibrinolysis</i> (2000).
DK	GIRARD et al., "Identification of the 1.4 KB and 4.0 KB Messages for the Lipoprotein Associated Coagulation Inhibitor and Expression of the Encoded Protein", <i>Thrombosis Research</i> , Vol. 55, pp. 37-50 (1989).
DL	GIRARD et al. "Functional Significance of the Kunitz-type Inhibitory Domains of Lipoprotein-Associated Coagulation Inhibitor", <i>Nature</i> , Vol. 338, pp. 518-520 (1989).
DM	GOEDDEL et al., "Synthesis of Human Fibroblast Interferon by <i>E. coli</i> ". <i>Nuci. Acids Res.</i> , Vol. 8, pp. 4057-4074 (1980).
DN	GRAHAM et al., "A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA", <i>Virology</i> , Vol. 52, pp. 456-467 (1973).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
51752-US-PCT
APPLICATION NO.
10/593,135
APPLICANT
ABLA CREASEY
FILING DATE
SEPTEMBER 18, 2006

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA	HALL et al., "The Association of TFPI with Artificial Surfaces", 6 th World Biomaterials Congress.
DB	HAMAMOTO et al., "Inhibitory Properties of Full-length and Truncated Recombinant Tissue Factor Pathway Inhibitor (TFPI)", <i>J. Biol. Chem.</i> , Vol. 268, pp. 8704-8710 (1993).
DC	HASKEL et al., "Prevention Arterial Reocclusion After Thrombolysis With Recombinant Lipoprotein-Associated Coagulation Inhibitor", <i>Circulation</i> , Vol. 84, pp. 821-827 (1991)
DD	HESS et al., "Cooperation of Glycolytic Enzymes", <i>J. Adv. Enzyme Reg.</i> , Vol. 7, pp. 149-167 (1968).
DE	HINSHAW, et al., "Survival of Primates in LD ₁₀₀ Septic Shock Following Steroid/Antibiotic Therapy", <i>J. Surg. Res.</i> , Vol. 28, pp. 151-170 (1989).
DF	HINSHAW et al., "Detection of the 'Hyperdynamic State' Sepsis in the Baboon During Lethal E. coli Infusion", <i>J. Trauma</i> , Vol. 23, pp. 361-365 (1983).
DG	HINSHAW et al., "Survival of Primates in LD ₁₀₀ Septic Shock Following Therapy with Antibody to Tumor Necrosis Factor (TNF α)", <i>Circulatory Shock</i> , Vol. 30, pp. 279-292 (1990).
DH	HITZEMAN et al., "Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique", <i>J. Biol. Chem.</i> , Vol. 255, pp. 12073-12080 (1980)
DI	HOLLAND et al., "The Primary Structures of Two Yeast Enolase Gene", <i>J. Biol. Chem.</i> , Vol. 256, pp. 1385-1395 (1981).
DJ	HOLLAND et al., "Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase, and Phosphoglycerate Kinase", <i>Biochemistry</i> , Vol. 17, pp. 4900-4907 (1978).
DK	HOLST et al., "Antithrombotic Properties of a Truncated Recombinant Tissue Factor Pathway Inhibitor in and Experimental Venous Thrombosis Model", <i>Haemostasis</i> , Vol. 23(suppl. 1), pp. 112-117 (1993).
DL	HSIAO et al., "High-Frequency Transformation of Yeast by Plasmids Containing the Cloned Yeast ARG ^a Gene", <i>PNAS (USA)</i> , Vol. 76, pp. 3829-3833 (1979).
DM	KAUS, "Pharmacokinetics and Pharmacodynamics of Recombinant Tissue Factor Pathway Inhibitor (r-TFPI)" Effect of IV and SC Heparin Administration", AAPS Annual Meeting (October 29, 1999).
DN	KEMME et al., "The Influence of Reduced Liver Blood Flow (LBF) on the Pharmacokinetics (PK) of Recombinant Tissue Factor Pathway Inhibitor (rTFPI)", 1999 American Society for Clinical Pharmacology Therapeutics Meeting.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
51752-US-PCT
APPLICATION NO.
10/593,135
APPLICANT
ABLA CREASEY
FILING DATE
SEPTEMBER 18, 2006

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	KNAUF et al., "Relationship of Effective Molecular size to Systemic Clearance in Rats of Recombinant Interleukin-2 Chemically Modified with Water-Soluble Polymers", <i>J. Biol. Chem.</i> , Vol. 263, pp. 15064-15070 (1988).
	DB	KRISTENSEN et al., Effect of Tissue Factor Pathway Inhibitor (TFPI) in the HEPTTEST® Assay and in an Amidolytic Anti Factor Xa Assay for LMW Heparin", <i>Thrombosis Flaemost</i> , CF.K. Schattauer Verlagsgesellschaft mbH (Stuttgart) Vol. 68, pp. 310-314 (1992).
	DC	KUNKEL et al., "Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection", <i>Proc. Nat. Acad. Sci. USA</i> , Vol. 82-488-492 (1985).
	DD	LASCH et al., "Heparin Therapy of Diffuse Intravascular Coagulation 9DEC", <i>Thrombos. Diathes. Haemorrh (Stuttg.)</i> , Vol. 33, pp. 105-106 (1974).
	DE	LEE et al., "Coagulation Inhibitors in Sepsis and Disseminated Intravascular Coagulation", <i>Intensive Care Med.</i> , Vol. 26, No. 11, pp. 1701-1706 (November 2000).
	DF	LEIGHTON, "Tissue Factor Pathway Inhibitor biology and Pharmacology", <i>ISTH</i> (August 14, 1999).
	DG	LEVI et al., "Novel Approaches to the Management of Disseminated Intravascular Coagulation", <i>Crit. Care Med.</i> , Vol. 28, No. 9(suppl.) pp. 520-4 (September 2000).
	DH	LINDHOUT et al., "Activation of Factor X and Its Regulation by Tissue Factor Pathway Inhibitor in Small-Diameter Capillaries Lined With Human Endothelial Cells", <i>Blood</i> , Vol. 79, pp. 2909-2016 (1992).
	DI	LYBERG et al., "Cellular Cooperation in Endothelial Cell Thromboplastin Synthesis", <i>British Journal of Haematology</i> , Vol. 53, pp. 85-95 (1983).
	DJ	MANIATAS et al., <i>Molecular Cloning – A Laboratory Manual</i> , Cold Spring Harbor Press, p. 202-203 (1982).
	DK	MARTIN et al., "Prospective National Study of Gram-Negative Bacterial (GNB) Sepsis – Natural History in the 1980s", Abstract No. 317, 29 th ICAAC Meeting, Houston (1989).
	DL	MATTEUCCI et al., "Synthesis of Deoxyoligonucleotides on a Polymer Support", <i>J. Am. Chem. Soc.</i> , Vol. 103, pp. 3185-3191 (1981).
	DM	MATYAL et al., "Extremely Low Doses of TFPI Decrease Mortality in a Rabbit Model of Septic Shock", <i>Intensive Care Med.</i> , 27(8):1274-1280 (August 2001).
	DN	MAXAM et al., "Sequencing End-labeled DNA with Base-Specific Chemical Cleavages.", <i>Math. Enzymol.</i> , Vol. 65, pp. 499-560 (1980).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
51752-US-PCT
APPLICATION NO.
10/593,135
APPLICANT
ABLA CREASEY
FILING DATE
SEPTEMBER 18, 2006

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	MESSING et al., "A System for Shotgun DNA Sequencing., <i>Nucl Acids Res.</i> , Vol. 9 pp. 309-321 (1981)
	DB	MMWR, <i>Septicemia</i> , Vol. 39, No. 2, pp. 31-34 (1987).
	DC	MMWR, <i>Hospitalizations</i> , Vol. 39, No. 43 pp. 777-785 (1987)
	DD	MÜLLER-BERGHAUS, "Pathophysiologic and Biochemical Events in Disseminated Intervascular Coagulation; Dysregulate of Procoagulant Anticoagulant Pathways", <i>Seminars in Thrombosis and Haemostasis</i> , Vol. 15, pp. 58-87 (1989).
	DE	NAWROTH et al., "Interleukin 1 Induces Endothelial Cell Procoagulant While Suppressing Cell-Surface Anticoagulant Activity", <i>PNAS (USA)</i> , Vol. 83 pp. 3460-3464 (1986).
	DF	NEMERSON, "Tissue Factor and Hemostasis", <i>Blood</i> , Vol. 71 pp. 1-8 (1988).
	DG	NOVOTNY et al., "Purification and Properties of Heparin-Releasable Lipoprotein-Associated Coagulation Inhibitor", <i>Blood</i> , Vol. 78, pp. 394-400 (1991).
	DH	NOVOTNY et al., "Purification and Characterization of the Lipoprotein-Associate Coagulation Inhibitor from Human Plasma", <i>J. Biol. Chem.</i> , Vol. 264:18832-18837 (1989).
	DJ	NORDFANG et al., "Inhibition of Extrinsic Pathway Inhibitor Shortens the Coagulation Time of Normal Plasma and of Hemophilia Plasma", <i>Thrombosis and Haemostasis, F.K. Schattauer Verlagsgesellschaft mbH (Stuttgart)</i> , Vol. 66, pp. 464-467 (1991).
	DK	NORDFANG et al., "The C-Terminus of Tissue Factor Pathway Inhibitor is Essential to Its Anticoagulant Activity", <i>Biochemistry</i> , Vol. 30, pp. 10371-10376 (1991).
	DL	OBUKOWICZ et al., "Secretion of Active Kringle-2-Serine Protease In <i>Escherichia coli</i> ", <i>Biochemistry</i> , Vol. 29, pp. 9737-9745 (1990).
	DM	OLINS et al., "A Novel Sequence Element Derived from Bacteriophage T7 mRNA Acts as <i>Escherichia coli</i> ", <i>Journal of Biological Chemistry</i> , Vol. 264, pp. 16973-16976 (1989).
	DN	Opal et al., "The Activity of Tissue Factor Pathway Inhibitor (TFPI) in Experimental Models of Superantigen-Induced and Polymicrobial Sepsis", <i>ICMC</i> , April 27, 1999, Abstract Only

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
51752-US-PCT
APPLICATION NO.
10/593,135
APPLICANT
ABLA CREASEY
FILING DATE
SEPTEMBER 18, 2006

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	DA	OSTERGAARD et al., Haemostasis, Vol. 23(suppl. 1), pp. 107-111 (1993).
	DB	OSTERUD et al., "Increased Tissue Thromboplastin Activity in Monocytes of Patients with Meningococcal Infection: Related to an Unfavourable Prognosis", <i>Thrombosis Haemost.</i> , Vol. 49, pp. 5-7 (1983)
	DC	OTT et al., "Reversible Regulation of Tissue Factor-Induced Coagulation by Phosphatidylinositol-Anchored Tissue Factor Pathway Inhibitor", <i>Arterioscler. Thromb. Vasc. Biol.</i> , Vol. 20, No. 3, pp. 874-882 (March 2000).
	DD	PEDERSEN et al., "Recombinant Human extrinsic Pathway Inhibitor", <i>J. Biol. Chem.</i> , Vol. 265, pp. 16786-16793 (1990)
	DE	PETERSEN et al., "Effect of Leukocyte Proteinases on Tissue Factor Pathway Inhibitor", <i>Thrombosis and Haemostasis</i> , of F.K. Schattauer Verlagsgesellschaft mbH (Stuttgart), Vol. 67, pp. 537-541 (1992)
	DF	QUEZADO et al., "Therapies Directed Against Endotoxin-Has the Time Come?", <i>Western J. of Med.</i> , Vol. 158, pp.424-425 (1993).
	DG	RAPAPORT, "Inhibition of Factor VIIa/Tissue Factor-Induced Blood Coagulation: With Particular Emphasis Upon a Factor Xa-Dependent Inhibitory Mechanism", <i>Blood</i> , 73: 359-365 (1989).
	DH	RAPAPORT, "The Extrinsic Pathway Inhibitor: A Regulator of Tissue Factor-Dependent <i>Thrombosis Haemost.</i> , Vol. 66; pp. 6-15 (1991).
	DJ	REINHART, "Overview of Tifacogin Clinical Development: Brussels. Scientific Conference Blood Coagulation", (2001).
	DK	RIVERS et al., "The Endotoxin-induced Coagulant Activity of Human Monocytes", <i>Br J. Haematol.</i> , Vol. 30, pp. 311-316 (1975).
	DL	SANDSET et al., "Coagulation Inhibitor levels in Pneumonia and Stroke: Changes due to Consumption and Acute Phase Reaction" <i>J. Internal Med.</i> , Vol. 225, pp. 311-316 (1989).
	DM	SANDSET et al., "Depletion of Extrinsic Pathway Inhibitor (EPI) Sensitizes Rabbits to Disseminated Intravascular Coagulation Induced with Tissue Factor: Evidence Supporting a Physiologic Role for EPI as a Natural Anticoagulant", <i>PNAS (USA)</i> , Vol. 88, pp. 708-712 (1991).
	DN	SANDSET et al., "Extrinsic Pathway Inhibitor in Postoperative/Posttraumatic Septicemia: Increased levels In Fatal Cases", <i>Haemostasis</i> , Vol. 19, pp. 189-195 (1989) (Abstract).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
51752-US-PCT
APPLICATION NO.
10/593,135
APPLICANT
ABLA CREASEY
FILING DATE
SEPTEMBER 18, 2006

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

D A	SANDSET et al., "Immunodepletion of Extrinsic Pathway Inhibitor Sensitizes Rabbits to Endotoxin-Induced Intravascular Coagulation and the Generalized Shwartzman Reaction", <i>Blood</i> , Vol. 78, pp. 1496-1502 (1991).
D B	SANDSET et al., "Heparin Induces Release of Extrinsic Coagulation Pathway Inhibitor (EFI)", <i>Thrombosis Res.</i> , Vol. 50, pp. 808-813 (1988).
D C	SANGER et al., "DNA sequencing with chain-terminating Inhibitors", <i>PNAS (USA)</i> , Vol. 74, pp. 5463-5467 (1977).
D D	SEHGAL et al., "Heterogeneity of Poly(I).Poly(C)-Induced Human Fibroblast Interferon mRNA Species", <i>Nature</i> , Vol. 288, pp. 95-97 (1980).
D E	SHAW et al., "A General Method for the Transfer of Cloned Genes to Plant Cells", <i>Gene</i> , Vol. 23, pp. 315-330 (1983).
D F	SHIMATAKE et al., "Purified λ Regulatory Protein cII Positively Activates Promoters for Lysogenic Development", <i>Nature</i> , Vol. 292, pp. 128-132 (1981).
D G	STEPHENSON et al., "Tissue Factor Pathway Inhibitor Delays the Development of Intimal Hyperplasia in a Porcine Vein-Grafting Model", American College of Surgery, March 15, 1999. Abstract
D H	STINCHCOMB et al., "Isolation and Characterization of a Yeast Chromosomal Replicator", <i>Nature</i> , Vol. 262, pp. 39-43 (1979).
D J	STRAUB, "A Case Against Heparin Therapy of Intravascular Coagulation", <i>Thrombos. Diathes. Haemorrh.</i> , Vol. 33, pp. 107-112 (1974).
D K	TAYLOR et al., "DEGR-Factor Xa Blocks Disseminated Intravascular Coagulation Initiated by <i>Escherichia coli</i> Without Preventing Shock or Organ Damage", <i>Blood</i> , Vol. 78, pp. 364-368 (1991).
D L	TAYLOR et al., "Lethal <i>E. Coli</i> Septic Shock is Prevented by Blocking Tissue Factor With Monoclonal Antibody", <i>Circulatory Shock</i> , Vol. 33, pp. 127-134 (1991).
D M	TAYLOR, "Baboon Model of <i>E. Coli</i> Sepsis: Summary of Staging, Mechanism, and Diagnostic Markers", in <i>Molecular Aspects of Inflammation</i> , 42. Colloquium Mosbach, Springer-Verlag Berlin, pp. 277-288 (1991).
D N	TSCHUMPER et al., "Sequence of a Yeast DNA Fragment Containing a Chromosomal TRP1 Gene", <i>Gene</i> , Vol. 10, pp. 157-166 (1980).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
51752-US-PCT
APPLICATION NO.
10/593,135
APPLICANT
ABLA CREASEY
FILING DATE
SEPTEMBER 18, 2006

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA	VALENTIN et al., "Simultaneous Presence of Tissue Factor Pathway Inhibitor (TFPI) and Replicator end the Low Molecular Weight Heparin has a Synergistic Effect in Different Coagulation Assays", <i>Blood Coagulation Fibrinolysis</i> , Vol. 2, pp. 629-635 (1991).
DB	VALENTIN et al., "Synergism Between Full Length TFPI and Heparin: Evidence for TFPI as an Important Factor for the Antithrombotic Activity of Heparin", <i>Blood Coagulation and Fibrinolysis</i> , Vol. 3, pp. 221-222 (1992).
DC	VALLET, "Microthrombosis in Sepsis", <i>Minerva Anesthesiol.</i> , Vol. 67, No. 4, pp. 298-301 (April 2001).
DD	VAN SOLINGEN et al., "Fusion of Yeast Spheroplasts", <i>J. Bact.</i> , Vol. 130, pp. 946-947 (1977).
DE	VAN DER POLL et al., "Dose-dependent Inhibition of Endotoxin-Induced Coagulation Activation by TFPI without Influencing the Fibrinolytic and Cytokine Response in Healthy Humans", <i>ISTH</i> (August 14, 1999).
DF	WARR et al., "Human Plasma Extrinsic Pathway-Inhibitor Activity: II. Plasma levels in Disseminated Intravascular Coagulation and Hepatocellular Disease", <i>Blood</i> , Vol. 74, pp. 994-998 (1989).
DG	WARR et al., "Disseminated Intravascular Coagulation In Rabbits Induced by Administration of Endotoxin or Tissue Factor: Effect of Anti- Tissue Factor Antibodies and Measurement of Plasma Extrinsic Pathway Inhibitor Activity", <i>Blood</i> , Vol. 75, pp. 1481-1489 (1990).
DH	WHERRY et al., "Monoclonal Antibody to Human Tumor Necrosis Factor (TNF Mab): Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), New Orleans, Louisiana, Oct. 17-20, (1993).
DJ	WUN et al., "Cloning and Characterization of a cDNA Coding for the Lipoprotein-Associated Coagulation Inhibitor Shows That It Consists of Three Tandem Kunitz-type Inhibitory Domains", <i>J. Biological Chemistry</i> , Vol. 263, pp. 6001-6004 (1988).
DK	WUN et al., "Immunoaffinity Purification and Characterization of Lipoprotein-Associated Coagulation Inhibitors from Hep G2 Hepatome, Chang Liver, and SK Hepatoma Cells", <i>J. Biol. Chem.</i> , Vol. 265, pp. 16096-16101 (1990).
DL	WUN et al., "Comparison of Recombinant Tissue Factor Pathway Inhibitors Expressed in Human SK Hepatoma, Mouse C127, Ba, pp. 54-59 (1992).
DM	YANG et al., "Comparison of Methods for Local Delivery of Tissue Factor Pathway Inhibitor to Balloon-injured Arteries in Rabbits", <i>Coron. Artery Dis.</i> , Vol. 10, No. 5, pp. 327-333 (July 1999).
DN	ZINSSER, "The Action of Chemotherapeutic Agents", <i>MicroBiology</i> , 17th ed., W. Jokik et al., eds., pp. 235-277 (1980).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
51752-US-PCT
APPLICATION NO.
10/593,135
APPLICANT
ABLA CREASEY
FILING DATE
SEPTEMBER 18, 2006

Group

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

DA	Supplementary Partial European Search Report dated February 6, 2007 in the corresponding European Application No. EP 02 778 529.4 - 2107
DB	BAJAJ et al., "Tissue Factor Pathway Inhibitor": Potential Therapeutic Applications", Thrombosis and Haemostasis, Vol. 78-7, pp. 471-477 (1997) XP009064749
DC	SPEICH et al., "Efficacy Safety, and Tolerance of Piperacillin/Tazobactam Compared to Co-Amoxiclav plus and Aminoglycoside in the Treatment of Severe Pneumonia". European Journal of Clinical Microbiology and Infectious Diseases, Vol. 17, No. 5, pp. 313-317 (May 1998) XP002416071
DD	KHOURI et al., "A Phase II Trial of Intraluminal irrigation with Recombinant Human Tissue Factor Pathway Inhibitor to Prevent Thrombosis in Free Flap Surgery". <i>Plast Reconstr. Surg.</i> , Vol. 107, No. 2, pp. 408-415 (2001)
DE	POLLER et al., "Fixed Minidose Warfarin: a New Approach to Prophylaxis Against Venous Thrombosis After Major Surgery", <i>British Medical Journal (Clinical Research Edition)</i> , Vol. 295, No. 6609, pp. 1309-1312 (November 21, 1987).
DF	OLTRONA et al., "Inhibition of tissue Factor-Mediated Coagulation Markedly Attenuates Stenosis After Balloon-Induced Arterial Injury in Minipigs", <i>Circulation</i> , Vol. 96, No. 2, pp. 646-652 (July 15, 1997).
DG	WATERER et al., "Septic Shock and Respiratory Failure in Community-Acquired Pneumonia have Different TNF Polymorphism Associations", <i>Am. J. Respir. Crit. Care Med.</i> , Vol. 163, No. 7, pp. 1599-1604 (June 2001).
DH	RUIZ et al., "Severe Community-Acquired Pneumonia. Risk Factors and Follow-Up Epidemiology", <i>Am. J. Respir. Crit. Care Med.</i> , Vol. 160, No. 3, pp. 923-929 (Sept. 1999).
DJ	
DK	
DL	
DM	
DN	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.